Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer. Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter re...

Descripción completa

Detalles Bibliográficos
Autores principales: del Muro, X García, Marcuello, E, Gumá, J, Paz-Ares, L, Climent, M A, Carles, J, Parra, M Sánchez, Tisaire, J L, Maroto, P, Germá, J R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375206/
https://www.ncbi.nlm.nih.gov/pubmed/11875692
http://dx.doi.org/10.1038/sj.bjc.6600121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375206/
https://www.ncbi.nlm.nih.gov/pubmed/11875692
http://dx.doi.org/10.1038/sj.bjc.6600121

Ejemplares similares